» Download Public Reports
About 1 300 reports
- Company report
- March 2013
- 3 pages
March 2013
... Response letter. As a result of its acquisition of king, pfizer has assumed the development and commercialization rights and obligations to remoxy and to the three other licensed oradur-based opioid drug ...
March 2013
... drugs, and sold companies at favorable prices for shareholders. Moreover, we believe they have significant credibility with the investment community. Each of our nominees qualifies as an independent ...
March 2013
... For patients in spain. Epidermolysis bullosa , scl Scleroderma, cf cystic fibrosis, hemo Prader-willi syndrome, xfr Fragile x syndrome. Direct non ...
May 2013
... Enabled xellia to successfully grow and transition the business to become leaders in the supply of key anti-infective products. Now, as we focus on the future and the further development of the business ...
April 2013
... Hexyontm/hexacima complements sanofi pasteur S product family of acp-ipv (acellular pertussis vaccine, inactivated poliovirus vaccine) combination vaccines. The new 6-in-1 vaccine will be available ...
March 2013
... Should be first line treatment if the depression is severe, 2 prior episodes, family history of depression and patient wants it continued While women 2/3 times to suffer depression than men, men 3 ...
May 2013
... Government organised a public tender for the hpv vaccines. This tender led to price reductions from 375 To 52. 53 Stroetmann k. A., Jones t ...
March 2013
... Side 5 unemployment and disability disability is often higher than unemployment source: oecd (data refer to the year 2008). Nav, 21.03.2013 Side 6 people with mental ill-health access ...
» Purchase Premium Reports
(From $ 125 - $ 10 988)
About 1 300 reports
- $ 11 691
- Industry report
- May 2013
- by Global Research & Data Services
This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different European countries. The studies provide essential market information ...
May 2013
$ 7 701
This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different Eastern European countries. The studies provide essential market ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
